Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Biomarker/Drug/Therapy development

Esmo 4 Biomarker-Drug-Therapy development

In this session, the speakers discuss the current developments in biomarkers and their usefulness in deciding the drug therapy in cancer patients. The focus of the discussion is phosphatase and tensin homolog (PTEN) expression loss study whose primary aim was to assess radiographic progression-free survival ( rPFS) in patients with PTEN loss. The discussion mentions combining Akt inhibition with androgen receptor blockade may improve rPFS in patients with mCRPC and that PTEN loss may be a predictive biomarker of response in patients with mCRPC.

Next video

Additional materials

  • Circulating Tumor Cells:

    Abstract 730PD: Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial

    Feng et al.

    Annals of Oncology 27 (Supplement 6): vi243–vi265, 2016

    Link: http://annonc.oxfordjournals.org/content/27/suppl_6/730PD.full.pdf

    (Awaiting permission for poster)


    Circulating tumor cells as biomarkers in prostate cancer

    Danila DC, Fleisher M, Scher HI

    Clin Cancer Res 2011;17:3903-12.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/21680546


    Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al.

    Clin Cancer Res 2008;14:6302-9.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/18829513


    Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.

    Lowes LE, Bratman SV, Dittamore R, Done S, Kelley SO, Mai S, et al.

    Int J Mol Sci 2016 ;17;1505

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/27618023

  • Circulating-free DNA:

    Abstract 59P:  Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy

    Wyatt et al.

    Annals of Oncology 27 (Supplement 6): vi15–vi42, 2016

    Link: http://annonc.oxfordjournals.org/content/27/suppl_6/59P.full.pdf

    (Awaiting permission for poster)


    Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

    Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, et al.

    JAMA Oncol 2016;2:1598-1606

    Link: https://www.ncbi.nlm.nih.gov/pubmed/27148695


    Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.

    Lowes LE, Bratman SV, Dittamore R, Done S, Kelley SO, Mai S, et al.

    Int J Mol Sci 2016 ;17;1505

    Link: https://www.ncbi.nlm.nih.gov/pubmed/27618023

  • Exosomes:

    Abstract 729PD: AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer

    Del Re et al.

    Annals of Oncology 27 (Supplement 6): vi243–vi265, 2016

    Link: http://annonc.oxfordjournals.org/content/27/suppl_6/729PD.full.pdf

    (Awaiting permission for poster)


    Identification of prostate cancer biomarkers in urinary exosomes

    Øverbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, et al.

    Oncotarget 2015;6:30357-76.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/26196085

  • PTEN Expression Loss:

    Abstract 718O: PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Bono et al.

    Annals of Oncology 27 (Supplement 6): vi243–vi265, 2016

    Link: http://annonc.oxfordjournals.org/content/27/suppl_6/718O.full.pdf


    PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate

    Eur Urol 2015;67:795-802.

    Link: PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate